Progression-free and overall survival of a modified outpatient regimen of primary intravenous/intraperitoneal paclitaxel and intraperitoneal cisplatin in ovarian, fallopian tube, and primary peritoneal cancer

Gynecologic Oncology

Volumn 125, Issue 3, 2012, Pages 621-624

  Barlin, Joyce N ^a   Dao, Fanny ^a   Zgheib, Nadim Bou ^a   Ferguson, Sarah E ^b   Sabbatini, Paul J ^a,c   Hensley, Martee L ^a,c   Bell Mcguinn, Katherine M ^a,c   Konner, Jason ^a,c   Tew, William P ^a,c   Aghajanian, Carol ^a,c   Chi, Dennis S ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b PRINCESS MARGARET HOSPITAL   (Canada)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Intraperitoneal chemotherapy; Modified regimen; Ovarian cancer; Survival

Indexed keywords

CISPLATIN; PACLITAXEL;

ABDOMINAL PAIN; ABDOMINAL SURGERY; ADULT; AGED; CANCER CHEMOTHERAPY; CHOLECYSTECTOMY; CONFERENCE PAPER; CYTOREDUCTIVE SURGERY; DRUG DOSE REGIMEN; DRUG FATALITY; DRUG TOLERABILITY; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; GASTROINTESTINAL TOXICITY; HISTOPATHOLOGY; HUMAN; INFECTION; INTESTINE RESECTION; LIVER RESECTION; MAJOR CLINICAL STUDY; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; OUTCOME ASSESSMENT; OUTPATIENT CARE; OVARY CANCER; OVERALL SURVIVAL; PANCREAS RESECTION; PERITONEUM CANCER; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; SPLENECTOMY; THROMBOCYTOPENIA; TUMOR VOLUME; UTERINE CERVIX CANCER; UTERINE TUBE DISEASE;

ADULT; AGED; AMBULATORY CARE; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FALLOPIAN TUBE NEOPLASMS; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; INFUSIONS, PARENTERAL; MIDDLE AGED; NEOPLASM STAGING; OVARIAN NEOPLASMS; PACLITAXEL; PERITONEAL NEOPLASMS; RETROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84861194164     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2012.03.027     Document Type: Conference Paper

References (10)

1. D.S. Alberts, P.Y. Liu, E.V. Hannigan, R. O'Toole, S.D. Williams, and J.A. Young Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer N Engl J Med 335 1996 1950 1955
2. M. Markman, B.N. Bundy, D.S. Alberts, J.M. Fowler, D.L. Clark-Pearson, and L.F. Carson Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group J Clin Oncol 19 2001 1001 1007
3. D.K. Armstrong, B. Bundy, L. Wenzel, H.Q. Huang, R. Baergen, and S. Lele Intraperitoneal cisplatin and paclitaxel in ovarian cancer N Engl J Med 354 2006 34 43
4. NCI Clinical Announcement on Intraperitoneal Therapy for Ovarian Cancer 2006 National Cancer Institute Accessed Dec 8, 2009, at http://www.cancer.gov/ clinicaltrials/developments/IPchemo-digest
5. E.L. Kaplan, and P. Meier Nonparametric estimation from incomplete observations J Am Stat Assoc 53 1958 457 481
6. D.S. Chi, C.C. Franklin, D.A. Levine, F. Akselrod, P. Sabbatini, and W.R. Jarnagin Improved optimal cytoreduction rates for stages IIIC and IV epithelial ovarian, fallopian tube, and primary peritoneal cancer: a change in surgical approach Gynecol Oncol 94 2004 650 654
7. N. Katsumata, M. Yasuda, F. Takahashi, S. Isonishi, T. Jobo, and D. Aoki Japanese Gynecologic Oncology Group. Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial Lancet 374 2009 1331 1338
8. E.A. Eisenhauer, W.W. ten Bokkel Huinink, K.D. Swenerton, L. Gianni, J. Myles, and M.E. van der Burg European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion J Clin Oncol 12 1994 2654 2666
9. G.F. Fleming, J.M. Fowler, S.E. Waggoner, L.J. Copeland, B.E. Greer, and I. Horowitz Phase I trial of escalating doses of paclitaxel combined with fixed doses of cisplatin and doxorubicin in advanced endometrial cancer and other gynecologic malignancies: a Gynecologic Oncology Group study J Clin Oncol 19 2001 1021 1029
10. J.A. Konner, D.M. Grabon, S.R. Gerst, A. Iasonos, H. Thaler, and S.D. Pezzulli Phase II study of intraperitoneal paclitaxel plus cisplatin and intravenous paclitaxel plus bevacizumab as adjuvant treatment of optimal stage II/III epithelial ovarian cancer J Clin Oncol 29 2011 4662 4668